USA – Judge Denies J&J Motion to Dismiss Pfizer Lawsuit Over Remicade

US District Court Judge Curtis Joyner on Friday denied Johnson & Johnson’s (J&J) attempt to scuttle a lawsuit brought by Pfizer over its failure to gain market penetration for its Remicade (infliximab) biosimilar Inflectra (infliximab-dyyb).

Pfizer alleges that J&J’s anticompetitive practices targeted both insurers and providers and involved exclusive contracts for Remicade, as well as myriad rebate games that prevented Pfizer and others from competing with Remicade.

“In essence, if an insurer refuses to grant exclusivity to Remicade, the insurer would be forced to pay a higher price on other J&J products in addition to Remicade. Pfizer identifies Simponi, Simponi Aria, and Stelara as other J&J products included in its multiproduct bundled rebate program,” Friday’s denial explains…